Search

everythinglearnresearchcommunity

for

Search:↓

A user is developing an AI-powered app for hair loss that includes features like hair loss stage detection and hairline tracking. They seek feedback to ensure the app is useful and emphasize privacy and affordability.

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

A user shared their positive experience with the telehealth service DocBright, highlighting its affordability and effectiveness in prescribing finasteride, oral minoxidil, and ketoconazole. They noted the service's unique ability to provide a prescription at age 17 but criticized the unprofessional communication with the dermatologist.

Setipiprant may help with hair maintenance but is not a guaranteed solution for everyone. Other treatments like minoxidil, finasteride, and topical spironolactone are discussed, with varying opinions on their effectiveness.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

Hair loss treatments like finasteride, minoxidil, and ketoconazole shampoo are discussed humorously, with skepticism about future cures. Users express frustration over the lack of a permanent solution and joke about investing in stocks or using time travel to solve baldness.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

Hair transplants and hair loss treatments like oral Fin and Min are discussed, with some humor about public figures' hair. Missing a single day of these treatments typically has little impact, but longer gaps can affect results.

A new light therapy claims to reduce hair loss markers by 92% using a specific wavelength range. Users discuss the cost and effectiveness of devices, with some expressing skepticism and others considering alternative treatments like red light therapy and vitamin D exposure.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

Early hair loss causes emotional distress, and common coping strategies like fitness and fashion are inadequate. Treatments like finasteride, minoxidil, dutasteride, hair systems, and scalp micropigmentation were tried but were unsatisfactory.

Efforts to find a Canadian dermatologist in the US to prescribe H&W's topical finasteride for hair loss. The user is willing to fund a crowd-share effort to identify prospects.

The user experienced hair regrowth using 0.5mg oral finasteride and the iRestore laser cap every other day, with reduced shedding. They also take collagen peptides and Nutrafol vitamins, though they are unsure of the latter's effectiveness.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The conversation is about hair loss treatments, specifically discussing the use of Minoxidil, Finasteride, and RU58841. A user inquired about the availability of Winlevi (clascoterone) for hair loss.

A user seeks a topical hair loss treatment without minoxidil, considering options like finasteride, dutasteride, caffeine, tretinoin, or prostaglandin analogues. Recommendations include products like Strut, Maximus, Zeuss, and custom formulas from compounding pharmacies.

A user sought treatment for hair loss through Cortina Health, where they were prescribed a specific topical solution containing Finasteride, Minoxidil, and Retinoic Acid. They are unsure if this unique combination is better than generic products and are seeking advice on whether to trust Cortina Health.

The conversation humorously discusses hair loss treatments, mentioning "oral miraclegro," "topical roundup," "spectracide," "Cow Dung mesotherapy," and "weekly Foot stepping sessions." The user jokingly considers switching to "weed and feed" as a treatment.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

The conversation discusses using topical finasteride for hair loss, with concerns about its safety around family members, especially pregnant women and infants. One user plans to try topical finasteride due to side effects from the pill.

A 22-year-old is experiencing hair loss and anxiety, trying treatments like topical finasteride, rosemary oil, caffeine, microneedling, low-level laser therapy, scalp massages, ketoconazole shampoo, and various vitamins. They are concerned about potential gynecomastia and are considering using minoxidil if current treatments don't stop hair loss or promote regrowth.

The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.

The user is using a hair loss treatment regimen that includes applying various topical solutions and taking oral medication. They are mixing their topical treatments to save time but are concerned about the effectiveness of the treatments when combined and stored.

Kintor Pharmaceutical's new hair loss treatment, KX-826, is entering the market. Users are eager to see its effectiveness before celebrating.

A dermatologist recommended a new supplement containing annurca apple, which reportedly doubles hair density and increases keratin after 60 days, to be used with finasteride. Some users are skeptical, considering it potentially ineffective or a marketing ploy, while others are open to trying it if it proves effective and affordable.

The conversation is about making topical finasteride using stemoxydine as a carrier. The user is considering buying Redken Cerafill Hair Re-Densifying Treatment (Stemoxydine) 90ml for this purpose.

First people receive Pyrilutamide on March 19th, 2022 for hair loss treatment. Users discuss obtaining the drug, its patent, and potential group buys.

An 18-year-old experiencing aggressive hair loss is considering whether to obtain a finasteride prescription through an online consult to save money instead of visiting a dermatologist. The user is seeking advice on the cost-effectiveness of these options.